Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

Add BPTH Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/19/2018 10:31:08 AM - Followers: 50 - Board type: Free - Posts Today: 3

Bio-path Holdings Inc.




Company description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the beginning of phase 2 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may apply for FDA acclerated status after testing is complete on 19 additional evaluable patients which is expected to occur in 2018.

CML combination drug safety study with Sprycel (Dasatinib) for BP1001 has allegedly begun at MD Anderson but we are awaiting FDA website comfirmation of same.

Patent protection for manufacturing their neutral lipid delivery system has occurred.
Bio-Path Holdings may also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected to occur in 2018.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.

While antisense drugs fell out of favor following Gilead's failed efforts there was some renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. At the present BPTH has no partnerships with other drug manufacturers.

This link to the company website describes their delivery technology:

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising additional funds the company has 6+ million in cash.

Bio-Path Holdings does not manufacture their drugs but uses contractors.
BPTH is presently traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:!/4292/presentation/2610

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $1.50 target. These are pre-reverse split recommendations.

Zack's rating now equals hold.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#3504   Pat, That is an excellent point I missed SJSTOCKSHARK 01/19/18 10:31:08 AM
#3503   So based on this analysis, it sounds like Pat Torney 01/19/18 10:16:18 AM
#3502   I agree completely Dawgster 01/19/18 12:05:56 AM
#3501   Rad, I agree the guns are re-holstered for SJSTOCKSHARK 01/18/18 10:09:15 PM
#3500   I received a call from attorney Brian O'Neill pvrad 01/18/18 09:28:43 PM
#3499   I currently live in Utah and was one Ping70 01/18/18 06:00:53 PM
#3498   There is absolutely no way PN turns over Pat Torney 01/18/18 04:06:26 PM
#3497   I have to agree with the last few too simple 01/18/18 03:31:56 PM
#3496   WORD AND RUNNIN, SJSTOCKSHARK 01/18/18 03:26:02 PM
#3495   I agree with Run. No scam here, and wordlender 01/18/18 01:49:44 PM
#3494   Pat, very nice synopsis. RS or no Runninonempty 01/18/18 11:27:46 AM
#3493   In my attempts to understand the history of Pat Torney 01/18/18 10:34:59 AM
#3492   My worry billow is a rs will drive tyroneweaver 01/18/18 06:12:14 AM
#3491   I have also been following this board for Billlowenswartz 01/18/18 01:35:31 AM
#3490   Rad, Thanks. SJSTOCKSHARK 01/17/18 11:46:42 AM
#3489   Sorry i meant reverse split not merger Dawgster 01/17/18 09:54:36 AM
#3488   Francis Pileggi was out of the office today pvrad 01/17/18 12:58:35 AM
#3487   Dawg, I agree with your post. SJSTOCKSHARK 01/16/18 10:17:48 PM
#3486   I am willing to participate I the Dawgster 01/16/18 07:26:26 PM
#3485   I doubt very seriously that this is a Dawgster 01/16/18 07:23:29 PM
#3484   Blairs and Rad, SJSTOCKSHARK 01/16/18 04:06:38 PM
#3483   Blairs, I thought I would check the pvrad 01/16/18 02:08:59 PM
#3482   SJ, I am calling Eckert Seamans Cherin & pvrad 01/16/18 01:02:44 PM
#3481   I am following this board with great interest blairsoldman 01/16/18 11:35:06 AM
#3480   SJ, Great stuff here. Thanks for the efforts. pvrad 01/16/18 10:01:52 AM
#3479   Rad, I read the company bylaws and also SJSTOCKSHARK 01/16/18 12:26:55 AM
#3478   The SEC website also says that the reverse pvrad 01/15/18 10:50:36 PM
#3477   Here is a link to the SEC's website. pvrad 01/15/18 10:45:10 PM
#3476   My my I went to Brigham Young University tyroneweaver 01/15/18 10:02:43 PM
#3475   My my I went to Brigham Young University tyroneweaver 01/15/18 10:02:42 PM
#3474   Bio-Path has been a wasatch front scam tyroneweaver 01/15/18 09:46:30 PM
#3473   Bio-Path has been a wasatch front scam tyroneweaver 01/15/18 09:46:30 PM
#3472   Has anyone read about Delaware supreme court ruling gerry57 01/15/18 05:15:16 PM
#3471   It apoears my son has a potential conflict Dawgster 01/15/18 04:24:03 PM
#3470   Understand. He will know better by eod. Dawgster 01/15/18 04:16:19 PM
#3469   For what its worth, I had this guy Pat Torney 01/15/18 12:33:36 PM
#3468   Does he feel comfortable with something like this? Pat Torney 01/15/18 11:40:06 AM
#3467   He is doing some preliminary research today and Dawgster 01/15/18 11:10:38 AM
#3466   I'll let you know on Monday Dawgster 01/13/18 11:49:19 PM
#3465   I'm in as well. pvrad 01/13/18 10:02:22 PM
#3464   Count me in. What type of retainer will SJSTOCKSHARK 01/13/18 04:57:32 PM
#3463   My son is an securities attorney. He may Dawgster 01/13/18 03:35:30 PM
#3462   Folks, I plan to research the NYSE issue SJSTOCKSHARK 01/13/18 02:02:37 AM
#3461   SJ and Pat, I attempted to send pvrad 01/12/18 09:39:18 PM
#3460   Does it have to be a DE attorney, Pat Torney 01/12/18 07:09:04 PM
#3459   SJ, I think these are the crucial questions pvrad 01/12/18 01:51:12 PM
#3458   You're right. I guess I had just Pat Torney 01/12/18 01:14:06 PM
#3457   Is the matter routine and would counting the SJSTOCKSHARK 01/12/18 01:05:34 PM
#3456   I guess we disagree. It seems pretty Pat Torney 01/12/18 12:56:40 PM
#3455   Pat, I hate to disagree but IMO it SJSTOCKSHARK 01/12/18 12:44:05 PM